R
  • 773.714.0705
  • Home
  • About Us
  • Specialty
  • Activities
    • Live
    • Online
  • Outcomes & Toolkits
New User? Login
Certificate Use Certificate Code

Overview

15th Annual Linda Morgante MS Nurse Leadership Program

SHARE WITH COLLEAGUE

Activity URL:

https://www.achlcme.org/detail/5153/15th-Annual-Linda-Morgante-MS-Nurse-Leadership-Program

Registration is closed for this activity.

15th Annual Linda Morgante MS Nurse Leadership Program
Format
Live Virtual Meeting
Time to Complete
5.00 hr(s).
Date
Saturday, October 12, 2024 09:00 AM CDT
Expires On
October 12, 2024

The journey of multiple sclerosis (MS) can be difficult for patients, but advances in the field have shifted the treatment paradigm from symptom management to disease modification. These therapeutic advances offer new hope, but effective care plans must be individualized and multi-dimensional, and the psychological, economic, and physical implications can be overwhelming for patients and their families. MS nurses are often the champions patients need to help understand therapies, manage symptoms, provide support and advocate for better, personalized health. Linda Morgante worked tirelessly as an MS nurse and touched the lives of thousands of patients, as well as her colleagues in the field. As an educator, Linda strove for excellence in nursing and to honor her legacy, the Linda Morgante MS Nurse Leadership Program, now in its 15th year, looks to help nurses, early in their professional career or looking to switch to MS nursing practice, by offering a virtual, full-day program featuring leading faculty in the field .This comprehensive program, offered virtually to best accommodate the schedules of busy nurses, features didactic presentations, office hours with faculty, Q&A, mentoring opportunities for ongoing collaboration and support. Register for this complimentary program today and invest in your professional development as an MS nurse.

This activity is intended for practicing nursing professionals who currently work in MS care or have an interest in entering the field.

The treatment of MS has evolved such that there are now a multitude of approved disease-modifying therapies (DMTs) for clinicians and patients to choose from when managing the disease. However, selection of the optimal medication for an individual patient remains an issue given a lack of guidance, variations in practice/across practitioners, and disease heterogeneity. Additionally, despite the evolution of DMTs, medication compliance over the long-term remains challenging. Nurses are tasked with ensuring patient wellness despite these hurdles. Education of this target audience remains critical in the face of outcomes-driven patient care and with respect to diagnosis, adverse event and symptom management, and coordination of care.

Upon completion of this activity, learners will be able to:
•Apply evidence-based diagnostic and assessment approaches for evaluating disease activity in the brain and spinal cord to develop individualized treatment plans in patients with MS
•Improve patient outcomes and adherence to therapy by identifying, assessing, and managing emerging MS-related symptoms and DMT-related adverse events.
•Employ treat-to-target strategies and precision medicine to improve patient long-term outcomes

Provided by the Academy for Continued Healthcare Learning (ACHL) and Annenberg Center for Health Sciences at Eisenhower.

Supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and TG Therapeutics, Inc.

Welcome and Introduction – Amy Perrin Ross and Colleen Harris (9:00am-9:15am)
Tributes to Linda Morgante and June Halper – Amy Perrin Ross and Colleen Harris
Disease Overview & Diagnosis – Aliza Ben-Zacharia (9:15am-10:10am)
Expert Discussion #1 – Amy Perrin Ross and Colleen Harris (10:10am-10:20am)
Break—(10:20am-10:30am)
Available MS Therapies – Marie Namey (10:30am-11:15am)
Treating to Target –Lynn McEwan (11:15am-11:35 am)
Case Presentation #1 – Lynn McEwan (11:35pm-11:55 am)
Lunch Break (11:55am-12:10 pm)
Symptom Management – Tricia Pagnotta (12:10pm-1:01pm)
Case Presentation #2 – Beverly Layton and Michelle Keating (1:01pm-1:19pm)
Break— (1:19pm-1:24pm)
Expert Discussion – Amy Perrin Ross and Colleen Harris (1:24pm-1:44pm)
The Lived Experience – Michelle Keating (1:44pm-2:09pm)
Conclusions and Thanks – Amy Perrin Ross and Colleen Harris (2:09pm-2:20pm)
*Times are in Central Time Zone

Colleen Harris, MN, NP
MS Clinic Nurse Practitioner 
University of Calgary-Foothills Medical Center MS Clinic
Calgary, Alberta, Canada
 
Amy Perrin Ross, APN, MSN
Advanced Practice Nurse 
Loyola University Chicago Medical Center
Maywood, Illinois
 
Aliza Ben-Zacharia, PhD, DNP, ANP, FAAN
Assistant Professor 
Hunter College NY and Mount Sinai School of Nursing
Nurse Practitioner
Independent NP Clinical Practice 
New York, New York
 
Michelle Keating, RN, MSCN-e
President of MS Bright Spots of Hope
St. Louis, Missouri 

Beverly Layton, RN, MSCN, BSN
MS Nurse Consultant
Birmingham, Alabama
 
Lynn McEwan, MScN
Nurse Practitioner Consultant
London, Ontario, Canada
 
Marie Namey APRN, MSCN-e
Independent MS Nurse Consultant
Cleveland, Ohio

Patricia Pagnotta, APRN
Nursing Clinical Preceptor
University of Central Florida 
Neurology Associates and MS Center of Greater Orlando
Orlando, Florida

The Annenberg Center for Health Sciences at Eisenhower and the Academy for Continued Healthcare Learning (ACHL) require that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. 

Colleen Harris, MN, NP (Chair)
Consulting Agreements: Amgen; EMD Serono; Hoffman Laroche; Novartis Pharmaceuticals; Sandoz

Amy Perrin Ross, APN, MSN (Chair)

Consulting Agreements: Alexion; Amgen; BMS; EMD Serono; Roche; Sandoz; TG Therapeutics; UCB

Aliza Ben-Zacharia, PhD, DNP, ANP, FAAN
Consulting Agreements: Biogen; EMD Serono 

Beverly Layton, RN, BSN
Consulting Agreements: Sanofi 

Lynn McEwan, NP, MScN
Advisory Board: Novartis; Roche

Marie Namey APRN, MSCN
Speaker’s Bureau: Sanofi-Genzyme 

Patricia Pagnotta, APRN
Consulting Agreements: Alexion; Biogen; BMS; EMD Serono; TG Therapeutics 

The following faculty have no relevant financial relationships to disclose:
Michelle Keating, RN, MSCN-e

ACHL and Annenberg Center staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

To receive credit, participants are required to participate in the virtual activity and complete the posttest and evaluation. Upon completing the surveys, a certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions, contact Katie Hacias at khacias@achlcme.org

In support of improving patient care, this activity has been planned and implemented by the Annenberg Center for Health Sciences at Eisenhower and the Academy for Continued Healthcare Learning. Annenberg Center for Health Sciences at Eisenhower is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 
 
Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 5.0 ANCC contact hours, which includes 1.50 pharmacology hours.

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: TBD 

Katie Hacias
khacias@achlcme.org
(773)714-0705 ext. 159
Related Activities
View All Activities

You are being redirected to another site.


footer-logo

308 S. Jefferson St.,
Suite 312,
Chicago, IL 60661

  • Phone: 773.714.0705
  • Fax: 773.714.0707
  • Home
  • Specialty
  • Sitemap
  • Privacy Policy
  • Contact Us
  • Follow us on Twitter
  • Like us on Facebook
  • Follow us on LinkedIn

Copyright © 2025 Academy for Continued Healthcare Learning. All Rights Reserved.

Processing...
×